Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 18/20 | 0.56 |
| ▸ | AURKA | O14965 | 15/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816236 | 0.93 | AURKB (0.55) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL1532395 | 0.86 | AURKA (0.61) | AURKBAURKASRCAURKCMAPKAPK2 | |
| SCHEMBL2202920 | 0.82 | AURKA (0.77) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL12657163 | 0.81 | AURKA (0.52) | AURKBAURKASIRT2MAPKAPK2 | |
| SCHEMBL1532353 | 0.81 | AURKB (0.53) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL2203133 | 0.80 | AURKB (0.60) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL15725191 | 0.79 | AURKB (0.56) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL12102920 | 0.79 | AURKA (0.50) | AURKBAURKASRCGSK3B | |
| SCHEMBL1078617 | 0.78 | AURKB (0.64) | AURKBAURKASRCGSK3B | |
| SCHEMBL12338812 | 0.77 | AURKB (0.58) | AURKBAURKASRCAURKCMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | AURKB 36/4885AURKA 47/4885SIRT2 433/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | AURKB 50/4885AURKA 37/4885SIRT2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.